Next Article in Journal
Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6–17 Years: An Immunobridging Trial
Next Article in Special Issue
Risk Factors for Impaired Cellular or Humoral Immunity after Three Doses of SARS-CoV-2 Vaccine in Healthy and Immunocompromised Individuals
Previous Article in Journal
Water-Soluble and Freezable Aluminum Salt Vaccine Adjuvant
Previous Article in Special Issue
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity
 
 
Due to scheduled maintenance work on our servers, there may be short service disruptions on this website between 11:00 and 12:00 CEST on March 28th.
Article

Article Versions Notes

Vaccines 2024, 12(6), 682; https://doi.org/10.3390/vaccines12060682
Action Date Notes Link
article html file updated 26 June 2025 05:20 CEST Update https://www.mdpi.com/2076-393X/12/6/682/html
article html file updated 19 June 2024 11:16 CEST Original file -
article supplementary file uploaded. 19 June 2024 11:13 CEST - https://www.mdpi.com/2076-393X/12/6/682#supplementary
article pdf uploaded. 19 June 2024 11:13 CEST Version of Record https://www.mdpi.com/2076-393X/12/6/682/pdf
article xml uploaded. 19 June 2024 11:13 CEST Update https://www.mdpi.com/2076-393X/12/6/682/xml
article xml file uploaded 19 June 2024 11:13 CEST Original file -
Back to TopTop